.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,357,336

« Back to Dashboard

Claims for Patent: 7,357,336

Title:Generation of therapeutic microfoam
Abstract: Improved therapeutic sclerosing microfoams and methods and devices for making them are provided that have advantage in producing a consistent profile injectable foam with minimal input by the physician yet using high volume percentages of blood dispersible gases, thus avoiding use of potentially hazardous amounts of nitrogen.
Inventor(s): Osman; Tariq (London, GB), Shilton-Brown; Sheila Bronwen (Brentwood, GB), Wright; David Dakin Iorwerth (High Wycombe, GB), Harman; Anthony David (Henley-on-Thames, GB), Boorman; Timothy David (Frinton on Sea, GB)
Assignee: BTG International Limited (London, GB)
Application Number:11/171,293
Patent Claims: 1. A method for producing a microfoam suitable for use in sclerotherapy of blood vessels, comprising: passing a mixture of at least one physiologically acceptable blood dispersible gas including oxygen, carbon dioxide or a mixture thereof and at least one aqueous sclerosant liquid through one or more passages thereby producing the microfoam, wherein a ratio of gas to liquid is such that the microfoam that is produced has a half-life of at least 2 minutes and a density ranging from 0.07 g/ml to 0.19 g/ml.

2. The method of claim 1, where the at least one physiologically acceptable blood dispersible gas comprises a mixture of 10 to 40% vol/vol carbon dioxide, 60-90% oxygen, and other physiological gases, the other physiological gases including under 30% vol/vol of nitrogen.

3. The method of claim 1, where the at least one physiologically acceptable blood dispersible gas comprises a mixture of 70% to 80% vol/vol oxygen, 20-30% carbon dioxide, the remainder being other physiological gases including nitrogen.

4. The method of claim 1, wherein the microfoam has a half-life of at least 2.5 minutes.

5. The method of claim 4, wherein the microfoam has a half-life of at least 3 minutes.

6. The method of claim 5, wherein the microfoam has a half-life of at least 4 minutes.

7. The method of claim 1, wherein the microfoam has a density ranging from 0.09 g/mL to 0.16 g/mL.

8. The method of claim 1, wherein the microfoam comprises at least 50% by number of the gas bubbles of 25 .mu.m diameter and above are of no more than 200 .mu.m diameter and at least 95% of these gas bubbles are no more than 280 .mu.m diameter.

9. The method of claim 1, wherein the microfoam comprises at least 50% by number of the gas bubbles of 25 .mu.m diameter and above are of no more than 150 .mu.m diameter and at least 95% of these gas bubbles are no more than 250 .mu.m diameter.

10. The method of claim 1, wherein the mixture of at least one physiologically acceptable blood dispersible gas and at least one aqueous sclerosant liquid is in the form of an aerosol, dispersion of bubbles in liquid or macrofoam.

11. The method of claim 1, wherein the ratio of gas to liquid used in the mixture is 1 gram sclerosant liquid to from 6.25 to 14.3 volumes of gas at standard temperature and pressure.

12. The method of claim 1, wherein the physiologically acceptable blood dispersible gas comprises a major proportion of carbon dioxide and/or oxygen.

13. The method of claim 12, wherein the physiologically acceptable blood dispersible gas comprises 99% carbon dioxide.

14. The method of claim 1, wherein the aqueous sclerosant liquid is a solution of polidocanol or sodium tetradecylsulfate (STS) in an aqueous carrier.

15. The method of claim 1, wherein a carrier comprises a saline solution.

16. The method of claim 1, wherein the gas is pressurized at 0.1 to 9 bar over atmospheric pressure.

17. The method of claim 1, wherein the gas is pressurized at 0.1 to 3 bar over atmospheric pressure.

18. The method of claim 1, wherein the aqueous solution contains a minor amount of alcohol.

19. The method of claim 1, wherein the mixture further comprises 1 to 10% vol/vol glycerol.

20. A method for producing a microfoam suitable for use in sclerotherapy of blood vessels, comprising: passing a mixture of at least one physiologically acceptable blood dispersible gas including 60-90% vol/vol oxygen, 10-40% vol/vol carbon dioxide or a mixture thereof and at least one aqueous sclerosant liquid through one or more passages thereby producing the microfoam, wherein a ratio of gas to liquid is such that the microfoam that is produced has a half-life of at least 2 minutes and a density ranging from 0.07 g/ml to 0.19 g/ml.

21. The method of claim 20, where the at least one physiologically acceptable blood dispersible gas comprises a mixture of 10 to 40% vol/vol carbon dioxide and other physiological gases, the other physiological gases comprising oxygen with under 30% vol/vol of nitrogen.

22. The method of claim 20, where the at least one physiologically acceptable blood dispersible gas comprises a mixture of 60% vol/vol or more oxygen, the remainder being carbon dioxide or carbon dioxide and nitrogen.

23. The method of claim 20, wherein the microfoam has a density ranging from 0.09 g/mL to 0.16 g/mL.

24. The method of claim 20, wherein the microfoam has a half-life of at least 2.5 minutes.

25. The method of claim 24, wherein the microfoam has a half-life of at least 3 minutes.

26. The method of claim 25, wherein the microfoam has a half-life of at least 4 minutes.

27. The method of claim 20, wherein the microfoam comprises at least 50% by number of the gas bubbles of 25 .mu.m diameter and above are of no more than 200 .mu.m diameter and at least 95% of these gas bubbles are no more than 280 .mu.m diameter.

28. The method of claim 20, wherein the microfoam comprises at least 50% by number of the gas bubbles of 25 .mu.m diameter and above are of no more than 150 .mu.m diameter and at least 95% of these gas bubbles are no more than 250 .mu.m diameter.

29. The method of claim 20, wherein the mixture of at least one physiologically acceptable blood dispersible gas and at least one aqueous sclerosant liquid is in the form of an aerosol, dispersion of bubbles in liquid or macrofoam.

30. The method of claim 20, wherein the ratio of gas to liquid used in the mixture is 1 gram sclerosant liquid to from 6.25 to 14.3 volumes of gas at standard temperature and pressure.

31. The method of claim 20, wherein the physiologically acceptable blood dispersible gas comprises a major proportion of carbon dioxide and/or oxygen.

32. The method of claim 20, wherein the aqueous sclerosant liquid is a solution of polidocanol or sodium tetradecylsulfate (STS) in an aqueous carrier.

33. The method of claim 20, wherein a carrier comprises a saline solution.

34. The method of claim 20, wherein the gas is pressurized at 0.1 to 9 bar over atmospheric pressure.

35. The method of claim 20, wherein the gas is pressurized at 0.1 to 3 bar over atmospheric pressure.

36. The method of claim 20, wherein the aqueous solution contains a minor amount of alcohol.

37. The method of claim 20, wherein the mixture further comprises 1 to 10% vol/vol glycerol.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc